For all of our advances in understanding the biology of a cancer cell, the cornerstone of therapy for advanced cancers remains drugs that are non-specifically cytotoxic. The challenge is to identify key molecular targets that underlie the malignant behavior of a cancer cell, and to target these directly. Since the phenotype of a cancer cell is largely driven by the pattern of genes expressed in the cell, much attention has focused on the inappropriate activation of transcription factors that regulate genes controlling proliferation, survival, self-renewal, and invasion. Two such oncogenic transcription factors are STAT3 and NF-kB. Through our research on developing targeted inhibitors of these proteins we have found that when STAT3 function is blocked by small molecule inhibitors, the activity of NF-kB often increases. This increase in NF-kB activity attenuates the effect of STAT3 inhibitors on cancer cells and raises a number of important mechanistic questions about the molecular and functional interaction between these proteins. To exploit these findings for cancer therapy, we set out to develop compounds that could simultaneously block the effects of STAT3 and NF-kB. Through a high throughput cell-based screen of approximately 200,000 compounds, and a related synthetic chemistry effort, we have identified two compounds that specifically block both of these transcription factors. These dual STAT3/ NF-kB inhibitors may represent a unique strategy for cancer therapy. We now propose to build on these observations to further understand the interaction between STAT3 and NF-kB in cancer cells, and to elucidate the potential for these dual inhibitors in the treatment of cancer. Focusing on breast cancer and multiple myeloma, tumors that frequently display co-activation of STAT3 and NF-kB, three aims will be pursued: (1) To discern the relationship between STAT3 inhibition and NF-kB activation in cancer cells. (2) To elucidate the molecular effects of dual STAT3/ NF-kB inhibitors in cancer cells. (3) To assess the effects of dual STAT3/ NF-kB inhibitors on the biology of cancer cells in cell culture and animal models. There is a great need for innovative treatments for advanced cancer that are targeted to the molecular defects driving the malignant behavior of these cells. The ultimate goal of this work is to elucidate the role that STAT3 and NF-kB are playing in cancer cells, and to determine the potential of simultaneously targeting both proteins as a form of molecular therapy for patients with cancer.
We have found that two key proteins, STAT3 and NF-kB, interact to drive the malignant behavior of a cancer cell, and we therefore developed molecules that can specifically inhibit these proteins. We now propose to determine how effective these chemicals will be as potential anti-cancer drugs. The focused goal of this work is to develop more effective and less toxic treatments for patients with cancer.
|Liu, Suhu; Marneth, Anna E; Alexe, Gabriela et al. (2018) The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv 2:3428-3442|
|Egusquiaguirre, Susana P; Yeh, Jennifer E; Walker, Sarah R et al. (2018) The STAT3 Target Gene TNFRSF1A Modulates the NF-?B Pathway in Breast Cancer Cells. Neoplasia 20:489-498|
|Heppler, Lisa N; Frank, David A (2017) Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors. Trends Cancer 3:816-827|
|Xiang, Michael; Kim, Haesook; Ho, Vincent T et al. (2016) Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128:1845-1853|
|Toniolo, Patricia A; Liu, Suhu; Yeh, Jennifer E et al. (2016) Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. Oncotarget 7:46301-46314|
|Toniolo, Patricia A; Liu, Suhu; Yeh, Jennifer E et al. (2015) Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J Immunol 194:3180-90|
|Hu, Tiancen; Yeh, Jennifer E; Pinello, Luca et al. (2015) Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. Mol Cell Biol 35:3284-300|
|Walker, S R; Liu, S; Xiang, M et al. (2015) The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene 34:1073-82|
|Lee, Robin E C; Walker, Sarah R; Savery, Kate et al. (2014) Fold change of nuclear NF-?B determines TNF-induced transcription in single cells. Mol Cell 53:867-79|
|Xiang, Michael; Birkbak, Nicolai J; Vafaizadeh, Vida et al. (2014) STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-?B to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal 7:ra11|
Showing the most recent 10 out of 14 publications